Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients

Ido Veisman; Shomron Ben-Horin

doi:10.1111/apt.16681

Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients

Ido Veisman, Shomron Ben-Horin^*

^*Corresponding author for this work

Internal Medicine

Sheba Medical Center at Tel Hashomer

Research output: Contribution to journal › Editorial

1 Scopus citations

Original language	English
Pages (from-to)	131-132
Number of pages	2
Journal	Alimentary Pharmacology and Therapeutics
Volume	55
Issue number	1
DOIs	https://doi.org/10.1111/apt.16681
State	Published - Jan 2022

Access to Document

10.1111/apt.16681

Cite this

@article{4b6c903433704f0785de2eb9c13ae86c,

title = "Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients",

author = "Ido Veisman and Shomron Ben-Horin",

note = "Funding Information: S.B.‐H. received consulting and advisory board fees and/or research support from AbbVie, MSD, Janssen, Takeda, Pfizer, GSK, Galmed Pharmaceuticals and CellTrion. I.V. is an employee of Galmed Pharmaceuticals. ",

year = "2022",

month = jan,

doi = "10.1111/apt.16681",

language = "אנגלית",

volume = "55",

pages = "131--132",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Editorial

T2 - tofacitinib post-marketing safety reports among ulcerative colitis patients

AU - Veisman, Ido

AU - Ben-Horin, Shomron

N1 - Funding Information: S.B.‐H. received consulting and advisory board fees and/or research support from AbbVie, MSD, Janssen, Takeda, Pfizer, GSK, Galmed Pharmaceuticals and CellTrion. I.V. is an employee of Galmed Pharmaceuticals.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85121112686&partnerID=8YFLogxK

U2 - 10.1111/apt.16681

DO - 10.1111/apt.16681

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.editorial???

C2 - 34907564

AN - SCOPUS:85121112686

SN - 0269-2813

VL - 55

SP - 131

EP - 132

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 1

ER -

Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients

Access to Document

Other files and links

Cite this